- Home
- HYFM vs GRCE Comparison
HYFM vs GRCE Comparison
Compare HYFM & GRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYFM
- GRCE
- Stock Information
- Founded
- HYFM 1977
- GRCE 2002
- Country
- HYFM United States
- GRCE United States
- Employees
- HYFM N/A
- GRCE N/A
- Industry
- HYFM Industrial Machinery/Components
- GRCE
- Sector
- HYFM Industrials
- GRCE
- Exchange
- HYFM Nasdaq
- GRCE NYSE
- Market Cap
- HYFM 31.3M
- GRCE 30.9M
- IPO Year
- HYFM 2020
- GRCE N/A
- Fundamental
- Price
- HYFM $0.55
- GRCE $2.99
- Analyst Decision
- HYFM Hold
- GRCE
- Analyst Count
- HYFM 2
- GRCE 0
- Target Price
- HYFM $0.70
- GRCE N/A
- AVG Volume (30 Days)
- HYFM 105.8K
- GRCE 43.5K
- Earning Date
- HYFM 11-07-2024
- GRCE 11-13-2024
- Dividend Yield
- HYFM N/A
- GRCE N/A
- EPS Growth
- HYFM N/A
- GRCE N/A
- EPS
- HYFM N/A
- GRCE N/A
- Revenue
- HYFM $200,158,000.00
- GRCE N/A
- Revenue This Year
- HYFM N/A
- GRCE N/A
- Revenue Next Year
- HYFM $3.48
- GRCE N/A
- P/E Ratio
- HYFM N/A
- GRCE N/A
- Revenue Growth
- HYFM N/A
- GRCE N/A
- 52 Week Low
- HYFM $0.43
- GRCE $1.98
- 52 Week High
- HYFM $1.20
- GRCE $3.60
- Technical
- Relative Strength Index (RSI)
- HYFM 28.99
- GRCE N/A
- Support Level
- HYFM $0.55
- GRCE N/A
- Resistance Level
- HYFM $0.62
- GRCE N/A
- Average True Range (ATR)
- HYFM 0.05
- GRCE 0.00
- MACD
- HYFM -0.01
- GRCE 0.00
- Stochastic Oscillator
- HYFM 0.06
- GRCE 0.00
About HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About GRCE GRACE THERAPEUTICS INC
Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage.